Is ibrutinib an oral medication?

Ibrutinib (Ibrutinib) is an oral drug widely used to treat a variety of B cell malignancies, including chronic lymphocytic leukemia (CLL), small Type lymphocytic lymphoma (SLL), lymphoid follicular lymphoma (FL) and Langerhans cell histiocytic lymphoma (MCL), etc. Ibrutinib belongs to a class of drugs called tyrosine kinase inhibitors, whose unique mechanism of action allows it to effectively inhibit the growth and division of leukemia or lymphoma cells.

Unlike many other leukemia or lymphoma treatments, ibrutinib is an oral medication that patients take by mouth in capsules or tablets. The advantages of this oral delivery method include convenience and patient autonomy, as patients can take the medication as prescribed by their doctor at home or other suitable places without the need to regularly travel to a hospital or clinic for injections or intravenous infusions.

The oral delivery form of ibrutinib generally makes treatment more acceptable, especially for patients who require long-term treatment. However, patients must strictly follow the doctor's recommendations when using ibrutinib, including dosage and medication time, to ensure the best therapeutic effect.

Ibrutinib is currently on the market in China and is included in medical insurance. The domestic price ranges from 10,000 to 20,000. Due to different medical insurance policies in different places, the price is also different. For specific reimbursement information, please consult the local hospital pharmacy or medical insurance bureau. The cheaper types of ibrutinib abroad are generic drugs, mainly Indian generic drugs, Bangladeshi generic drugs and Laos generic drugs, with prices ranging from a few hundred to several thousand yuan. And the ingredients of generic ibrutinib drugs are basically the same as those of domestic ibrutinib drugs.